Transgenic mice have been used to study gene function and regulation by introducing inducible or tissuespecific transgenes. This approach is generally limited to studying gene function in adult mice since ectopic expression of many interesting genes is disease causing or may be lethal to the developing embryo. To extend the utility of the transgenic mouse system to the early stages of embryogenesis, we have developed a two-tiered method of gene regulation to control transgene expression. Our multiplex gene regulatory system (MGR) allows the establishment of transgenic lines that harbor inducible potentially lethal transgenes. These inducible transgenes are activated only when mated to a second transgenic animal. Induction in the MGR system provides a high degree of temporal and spatial control over transgene expression and should be suitable for engineering "gain of function mutations" for many developmental genes.
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The multiplex gene regulatory (MGR) system consists of a transactivating gene product and its target transresponding promoter sequence. Our system is based on the observed transactivation of the immediate-early (IE) genes of herpes simplex virus (HSV-1) by the transactivator virion polypeptide VP16, (Vmw65, TIF) during HSV-1 infection. All of the IE genes of HSV-1 contain a cis-acting sequence (TAAT-GARAT) that is necessary and sufficient for transactivation by the VP16 gene product (1) (2) (3) (4) (5) . The VP16 protein is not a DNA binding protein but mediates transactivation of the IE promoters by forming a protein-protein complex with a cellular DNA binding factor (6) (7) (8) (9) . The cellular factor involved in this complex appears to be the ubiquitously expressed octamer binding protein (9, 10) . The MGR system utilizes these components [the IE promoter of infected cell polypeptide (ICP4) and the VP16 transactivator] to produce the inducible two-tiered regulatory network illustrated in Fig.  1 . One transgenic mouse line, the transresponder, contains the gene of interest regulated by the ICP4 promoter element. A second transgenic line, the transactivator, contains the VP16 gene regulated by an inducible or tissue-specific promoter. When the transresponder and transactivator lines are mated, the offspring that inherit both transgenes (boxed region of Fig. 1 (14, 15) . In both of these studies, the LTR-regulated target gene exhibited high basal levels ofactivity, and expression ofthe transactivator (TAT and tax) produced deleterious oncogenic phenotypes (14) (15) (16) . Unlike the oncogenic HIV and HTLV-1 viruses, HSV-1 is a lytic virus with a very broad host range. While small portions of the HSV-1 genome can transform tissue culture cells (17, 18) , these sequences are not associated with the VP16 transactivator. Moreover, transformation of tissue culture cells by HSV-1 is independent of viral gene expression. The broad HSV-1 host range and the apparent nontransforming character of VP16 suggested to us that a combination of the IE promoter element and the VP16 transactivator might produce a useful two-tiered regulatory network capable of controlling transgene expression in most murine tissues.
METHODS
Plasmids and DNA Preparation. The plasmid pPOH14 contains the 360-base-pair (bp) Sma I/BamHI promoter fragment of ICP4 (IE175) linked to the coding sequences for chloramphenicol acetyltransferase (CAT) along with the simian virus 40 splice and polyade-nylylation signals (19) . This insert was excised from the plasmid and the 2.1-kilobase (kb) IE-CAT transgene was gel-purified prior to microinjection. The coding and polyadenylylation sequences for the HSV-1 transactivator VP16 were derived from pCA15 (19 The second transgenic line, the transactivator (right), contains the HSV-1 transactivator VP16. In this example, VP16 is regulated by a neurospecific promoter element from the murine NF-L gene (11, 12 (22), centrifuged, and the supernatants were collected. Supernatants were stored at -20°C until used. CAT assays were as described by Gorman (23 Fig. 2A . 
scarification with HSV-1 (KOS). All of the tested lines exhibited specific CAT induction in the infected animals. Strong induction of CAT was observed in lines IE-CAT8 and -35 (Fig. 2B) , while the other two lines exhibited easily detected, although lower, levels of CAT activity (data not shown). The differences in CAT activity between the four lines may be due to integration site-specific position effects or, alternatively, due to differences in the degree of infection and subsequent viral regulation of the IE promoters. These experiments demonstrate that the IE promoter element, in transgenic mice, is a tight promoter with very little activity in the absence of VP16. Moreover, the lack of activity in the uninduced state appears to be maintained at a high frequency since four of four independent transgenic lines all exhibited no CAT activity in a variety of tissues, yet they maintained their inducible character.
We have also derived three founder mice that contain a murine NFT transgene (11, 12) . Only one of these animals (NFT4) expresses the VP16 gene product as assayed by its ability to induce CAT when mated to the IE-CAT8 line (Figs.  3 and 4) . When crossed to a female homozygous for the IE-CAT8 transgene (Fig. 3B) , the NFT4 founder segregated two unique VP16-specific restriction patterns (Fig. 3A) , suggesting that the NFT4 male has two unlinked sites of integration. One integration site yields two restriction fragments of 2.8 and 3.2 kb (Fig. 3B, lanes 1, 6, and 8 ) and appears to be inactive since offspring with this integration site exhibit no CAT activity in any tissues (Fig. 3C, lanes 1, 6, and 8; Fig.  4 ). The other integration site is active and produces a single 3.2-kb restriction fragment (Fig. 3A, lanes 2, 4, 7, and 9 ). The offspring that inherited this active integration site have easily detected levels of CAT activity in the brain and spinal cord Fig. 3 were further analyzed for the tissue specificity of CAT expression. Samples of liver (L), spleen (S), intestine (I), and heart (H) in addition to the spinal cord (SC) and brain (B) were assayed for CAT. In this experiment, a 50-fold excess of protein was used to assay the nonneuronal tissues relative to the brain and spinal cord samples. Offspring with the active VP16 integration site (offspring 2 and 9) exhibit CAT activity in the brain, spinal cord, and heart. Animals that did not inherit the VP16 gene (offspring 3) or that inherited the inactive integration site (offspring 6) exhibit no significant CAT activity in any of the tested tissues. ( Fig. 3A ; lanes 2, 4, 7, and 9). A weak level of CAT is also apparent in the heart, but not the liver, spleen, or intestine (Fig. 4 ). These results demonstrate that mice expressing VP16 can be established, that VP16 expression in the central nervous system is not detrimental to the developing embryo, and that transactivation by VP16 is tissue specific. Only those offspring (lanes 2, 4, 7, and 9) with the single 3.2-kb restriction fragment exhibit CAT activity within the neuronal tissues. No significant CAT activity is present in the offspring that lack the VP16 transgene or contain the 2.8-and 3.2-kb restriction pattern. Equal volumes of protein extract were used for each CAT assay.
DISCUSSION
The MGR system was created to assist in the analysis of developmental gene function. Previous use of transgenic mice to study gene function has regulated transgene expression by either relying on an inducible promoter, such as metallothionein (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) , or using tissue-specific promoters to target transgene expression to specific, generally dispensable, organs or tissues (36) (37) (38) (39) (40) (41) (42) . A more general use of transgenic mice to analyze developmental gene function would require both an inducible method of gene regulation, so that transgenic lines containing the gene of interest can be established, and a highly versatile means of transgene induction capable of matching the sometimes complex spatial patterns of developmental gene expression. The current single-tiered regulatory methods do not provide these capabilities since they necessarily have some degree of unregulated developmental expression (both inducible and tissuespecific promoters) or suffer a limited experimental ability to control the time and pattern of transgene expression. The MGR system we have described permits the establishment of transgenic lines containing IE-regulated genes. The IEregulated transgene can be activated in any variety of tissues during development simply by mating with a second transgenic mouse that contains the VP16 transactivator, regulated Genetics: Byrne and Ruddle by a promoter with the appropriate specificity. In addition, the MGR system makes it possible to simultaneously induce two or more IE-regulated transgenes within a single embryo. This capability is unique to the two-tiered regulatory approach and should be very useful for studying the interactions between developmental regulatory gene products.
There are two important criteria that are necessary for the MGR process to be useful for the analysis of developmental gene function. The IE promoter element should have very low basal activity in the absence of VP16 and expression of VP16 should not be oncogenic or produce developmental abnormalities. We have demonstrated that the 360-bp IE promoter of ICP4 has very little basal activity in the adult eye (Fig. 2B) and in newborn liver, kidney, spleen, brain, spinal cord, heart, lung, and intestine ( Fig. 2A) . We have also been unable to detect CAT activity in transgenic embryonic tissues (data not shown). In contrast, transient transfection assays with the same IE promoter consistently exhibit a high basal level ofexpression in several different tissue culture cell lines (1, 19, 25) . In these experiments, the basal level of IE expression is linearly related to the size and number of TAATGARAT sequences present in the promoter. It is likely that the high number of unintegrated plasmid molecules present in transfected cells can account for the observed difference in IE basal activity. We are aware of only one case in which stable cell lines with IE-regulated genes were produced. In this study, Mosca et al. (24) used a 1900-bp ICP4 promoter to regulate the human interferon and CAT reporter genes. Both of the IE-regulated constructs exhibited significant levels of basal expression. This high level of basal expression may be due to the size of the ICP4 promoter, which in this case included a HSV origin of replication, or may possibly result from the in vitro culture conditions. In any case, the results presented here strongly indicate that in transgenic mice the 360-bp IE promoter element has a very low level of basal activity in a wide spectrum of tissues.
In addition to a low basal state for the IE-regulated transgene, the MGR process requires that expression of the transactivator VP16 should not produce oncogenic or developmental abnormalities. We have demonstrated that expression of the VP16 gene product in the central nervous system does not affect the development or viability of the mouse. The NFT4 founder animal and his offspring with the active integration site are all apparently healthy, breed well, and exhibit no signs of tumor development. Other transactivator lines that we have derived express VP16 early during development in both neuronal and nonneuronal tissues and exhibit no deleterious effects (data not shown). While this does not preclude the possibility of subtle neurological changes, these results indicate that expression of VP16 may be well tolerated in a variety of tissues.
In earlier experiments, we were unsuccessful in deriving a transactivator line using a f-actin-regulated VP16 construct.
There have been several recent insights into the mechanism of VP16 transactivation that may explain the lethality of the .8-actin-VP16 transgene. Induction by VP16 requires an interaction with at least one other cellular factor, most likely the octamer binding protein (9, 10 
